$DAVA

Butcher Patrick sold $2K of DAVA

Butcher Patrick sold 533 shares of Endava plc (DAVA) at $2.88 on 2026-06-30.

Original reporting
SEC EDGAR · Butcher Patrick
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DAVA
Neutral
low confidence
Mentioned
$DAVA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DAVANeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (533 shares at $2.88) and the absence of a disclosed pre-arranged 10b5-1 plan.

02

Market read

Traders may note incremental sentiment from insider selling, but there is no fundamental catalyst or guidance change in the text.

03

What to watch

The filing does not state reasons for the sale, and the disclosed size ($1,535) is typically too small to be a reliable signal versus broader market or company catalysts.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-02, sale dated 2026-06-30

Background

The article is a SEC Form 4 insider transaction disclosure for Endava plc (DAVA).

Company-level read

Ticker impact

$DAVANeutralLow confidence
Context

Endava director Patrick Butcher filed a Form 4 open-market sale of 533 shares at $2.88 on 2026-06-30.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and should fade unless more insider selling or new fundamentals emerge.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the article provides no accompanying guidance, operational change, or material transaction context beyond the sale details.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine liquidity events and may not signal reduced confidence, especially without any other negative company-specific news.

Key entities

  • Endava plc

    Subject of the Form 4 insider transaction disclosure.

  • Patrick Butcher

    Director who sold 533 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DAVAMed

Here is Why Endava (DAVA) is One of the Underperforming Tech Stocks to Buy According to Analysts

Endava (NYSE:DAVA) reported FQ3 2026 revenue of £178.5 million, down 8.4% year over year, citing uneven demand and longer deal cycles. The company recorded a £364.6 million goodwill impairment and related tax charges, resulting in a diluted loss per share of £7.55. For FQ4, it expects revenue of £181.0–£185.0 million and adjusted diluted EPS of £0.09–£0.13.

$SIONMed

RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).